CelLBxHealth PLC Announces Board Changes

Rhea-AI Summary

CelLBxHealth plc (OTC:ANPCF) announced board changes effective immediately on 12 January 2026. Peter Collins was appointed Chief Executive Officer and Klaas de Boer, Kim Oreskovic and Benjamin Hart were appointed as Non-Executive Directors. Separately, Non-Executive Director Joseph Eid will step down from the board, effective 31 January 2026. The announcement states required AIM Rule 17 and Schedule 2(g) information is provided and that the disclosure is deemed inside information under the EU Market Abuse Regulation.

Positive

• Peter Collins appointed Chief Executive Officer (effective immediately)
• Three new Non-Executive Directors appointed (immediate effect)
• Board gains additional life sciences expertise per company statement

Negative

• Non-Executive Director Joseph Eid to step down on 31 January 2026
• Board transition may require short-term governance adjustments

Key Figures

Publication date: January 12, 2026 Prior announcement date: 15 December 2025 Director step-down date: 31 January 2026 +1 more

4 metrics

Publication date January 12, 2026 Announcement of board appointments and resignation timing

Prior announcement date 15 December 2025 Reference date for earlier board change communication

Director step-down date 31 January 2026 Effective date for Joseph Eid leaving the board

EU Market Abuse Regulation 596/2014 Cited as governing inside information in the announcement

Market Reality Check

Price: $0.0168 Vol: Volume 200,000 is 17.15x ...

high vol

$0.0168 Last Close

Volume Volume 200,000 is 17.15x the 20-day average of 11,660, indicating elevated trading interest ahead of this governance update. high

Technical Shares at 0.0168 are trading below the 200-day MA of 0.19 and sit at the 52-week low, 95.2% below the 52-week high of 0.35.

Peers on Argus

The stock fell 14.72% while key peers were mixed: BMKDF up 6.28%, IZOZF up 2.9%,...

The stock fell 14.72% while key peers were mixed: BMKDF up 6.28%, IZOZF up 2.9%, and ANPCY down 1.47%. This divergence points to a company-specific move rather than a sector-wide rotation.

Historical Context

2 past events · Latest: Oct 16 (Neutral)

Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Oct 16	Leadership appointments	Neutral	-47.7%	Announced interim CEO, senior advisor, and rebrand to CelLBxHealth.
Sep 12	Board departures	Negative	-59.3%	CEO and Finance Director agreed to step down after shareholder talks.

Pattern Detected

Recent leadership and board announcements have coincided with sharp negative price reactions, suggesting governance changes have been a key overhang.

Recent Company History

Over recent months, the company has undergone substantial leadership transition. On 12 September 2025, ANGLE plc announced the CEO and Finance Director would step down after shareholder discussions, and shares fell 59.28%. On 16 October 2025, it announced Peter Collins as interim CEO, Klaas de Boer as senior advisor, and a planned renaming to CelLBxHealth plc, with a 47.7% decline. Today’s formal board appointments and another director’s planned departure continue this governance reshaping trend.

Market Pulse Summary

This announcement continues CelLBxHealth’s board transition, confirming Peter Collins as CEO and add...

Analysis

This announcement continues CelLBxHealth’s board transition, confirming Peter Collins as CEO and adding several non-executive directors while another director prepares to step down on 31 January 2026. It follows prior leadership changes and the rebranding from ANGLE plc, marking further evolution in governance. With the share price at the 52-week low and well below the 0.19 200-day MA, investors may focus on how the new board composition translates into strategic actions and operational milestones.

Key Terms

circulating tumour cell, non-executive director, inside information, eu market abuse regulation, +2 more

6 terms

circulating tumour cell medical

"a leader in circulating tumour cell (CTC) intelligence, with tests and services"

Circulating tumour cells are cancer cells that have broken away from a solid tumour and entered the bloodstream, like seeds carried from a tree by the wind. They matter to investors because tests that detect or count these cells can indicate whether a cancer is spreading, how well a treatment is working, and may support development or approval of therapies and diagnostics, affecting the commercial value of related medical products and companies.

non-executive director technical

"Klaas de Boer as Non-Executive DirectorKim Oreskovic as Non-Executive Director"

A non-executive director is a member of a company’s board who does not work for the company day-to-day but provides independent oversight, strategic guidance and checks on management. For investors, they matter because they act like an impartial referee or outside advisor, helping ensure decisions protect shareholder interests, reduce risks of poor governance, and add credibility to financial reporting and long-term strategy.

inside information regulatory

"announcement is deemed by the Company to constitute inside information as stipulated"

Information not available to the public that, if known, would likely cause a company’s stock or bonds to rise or fall—for example, undisclosed earnings, deals, product results, or management plans. It matters because trading on that information gives an unfair advantage, can distort market prices, and is typically illegal or subject to strict rules, so investors watch for proper disclosure and compliance to protect fair, transparent markets.

eu market abuse regulation regulatory

"as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part"

A set of EU-wide rules that prevent cheating in financial markets by banning insider trading, market manipulation, and misleading disclosure; it also requires timely public release of key company information so everyone can play on a level field. For investors, it reduces the risk that prices are driven by secret deals or false signals, making markets fairer and more reliable for deciding when to buy or sell — like referees enforcing fair play in a game.

aim rules for companies regulatory

"information required in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies"

AIM rules for companies are the set of listing and ongoing obligations that firms must follow to trade on the AIM market, a venue for smaller or growing companies. They matter to investors because the rules require regular financial updates, disclosure of major events and standards of conduct—like a rulebook that helps ensure companies behave predictably and share the information investors need to judge risk and value.

regulatory information service regulatory

"Upon the publication of this announcement via a regulatory information service"

A regulatory information service is an authorized public platform that publishes official company announcements and required filings — such as financial results, board changes, takeover notices and regulatory disclosures — so the market gets the same information at the same time. It matters to investors because it acts like an official bulletin board: timely, identical access to material news helps ensure fair trading, reduces surprises, and lets investors make informed decisions.

AI-generated analysis. Not financial advice.

GUILDFORD, SURREY / ACCESS Newswire / January 12, 2026 / CelLBxHealth plc (AIM:CLBX), a leader in circulating tumour cell (CTC) intelligence, with tests and services supporting research, drug development and clinical oncology, is pleased to announce that further to the announcement of 15 December 2025, that the following have been appointed to the board with immediate effect:

• Peter Collins as Chief Executive Officer

• Klaas de Boer as Non-Executive Director

• Kim Oreskovic as Non-Executive Director

• Benjamin Hart as Non-Executive Director

The information required in accordance with Rule 17 and Schedule 2(g) of the AIM Rules for Companies is detailed at the end of this announcement.

Separately Non-Executive Director, Joseph Eid will step down from the board, effective 31 January 2026.

Jan Groen, Executive Chair of CelLBxHealth plc, said: "We welcome Peter and the non-executives to the board. Their extensive expertise, combined with additional life sciences experience will significantly enhance the board's capabilities as we focus on strategic opportunities and delivering long-term shareholder value. We would also like to thank Joseph for his assistance over his tenure and wish him all the best for the future."

For further information:

CelLBxHealth plc Peter Collins, Chief Executive Officer	+44 (0) 1483 343434 investor@CelLBxHealth.com
Cavendish (NOMAD and Broker) Geoff Nash / Isaac Hooper / Hamza Munshi (Corporate Finance) Sunila de Silva (Corporate Broking) Nigel Birks (Life Science Specialist Sales)	+44 (0) 20 7220 0500
FTI Consulting Simon Conway, Ciara Martin, Sam Purewal	+44 (0) 203 727 1000

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014) as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018, as amended. Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

About CelLBxHealth plc

CelLBxHealth plc is a leading CTC intelligence company specialising in innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology. Its patent-protected Parsortix® platform harvests CTCs from blood and can be integrated with existing laboratory instruments for comprehensive downstream analysis - including whole-cell imaging, proteomic profiling and full genomic workflows.

Commercial activities centre on (1) Product Sales: Accelerating Parsortix platform adoption and consumable sales through CROs and clinical lab partnerships. (2) Laboratory services: Clinical trial support and assay development (3) Lab Developed Tests (LDTs): Strategic partnerships combined with a focused in-house development programme.

The product portfolio comprises the Parsortix® platform with associated consumables and assays. Laboratory services are delivered from CelLBxHealth's GCLP certified UK laboratory, providing bespoke clinical-trial support and assay development.

For more information, visit https://cellbxhealth.com/.

AIM Rules Schedule 2 (g) information

The directorships and partnerships currently held by Peter Michael Collins, aged 67, and over the five years preceding the date of this announcement are as follows:

Current directorships	Previous directorships held in the past five years
	Saga Diagnostics UK Limited SAGA Diagnostics AB Collins Biotech Consulting SRL

The directorships and partnerships currently held by Klaas De Boer, aged 60, and over the five years preceding the date of this announcement are as follows:

Current directorships	Previous directorships held in the past five years
Tsjukemar Ltd General Fusion Inc Xeros Technology Group plc SmartKem Inc Smartkem Ltd Fashion for Good BV	Entrepreneurs Fund Management LLP Entrepreneurs Fund Management Services Ltd veriNOS Pharmaceuticals GmbH (Previously known as vasopharm GmbH) Stichting Administratiekantoor Bellevue

The directorships and partnerships currently held by Benjamin Jacob Hart, aged 38, and over the five years preceding the date of this announcement are as follows:

Current directorships	Previous directorships held in the past five years
	Applied Technology Partners LLC

The directorships and partnerships currently held by Kimberley Anne Oreskovic, aged 60, and over the five years preceding the date of this announcement are as follows:

Current directorships	Previous directorships held in the past five years
Innoviance Investments B.V. Innoviance Consulting B.V.

There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Cellbxhealth PLC

View the original press release on ACCESS Newswire

FAQ

Who was named CEO of CelLBxHealth (ANPCF) on January 12, 2026?

Peter Collins was appointed Chief Executive Officer effective immediately.

Which new Non-Executive Directors joined CelLBxHealth (ANPCF) in January 2026?

Klaas de Boer, Kim Oreskovic and Benjamin Hart were appointed as Non-Executive Directors effective immediately.

When will Non-Executive Director Joseph Eid leave the CelLBxHealth (ANPCF) board?

Joseph Eid will step down from the board effective 31 January 2026.

Does the CelLBxHealth (ANPCF) announcement reference AIM Rule 17 requirements?

Yes, the announcement says the information required under AIM Rule 17 and Schedule 2(g) is provided.

Is the CelLBxHealth (ANPCF) board change declared inside information?

Yes, the company deems the board changes to constitute inside information under the EU Market Abuse Regulation.